MindWalk Holdings (HYFT) Return on Invested Capital (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Return on Invested Capital of 0.0% for Q2 2026, up 69.0% year-over-year from 0.0% in Q2 2025, and down 48.81% quarter-over-quarter from 0.0% in Q1 2026.
MindWalk Holdings (HYFT) Return on Invested Capital (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Return on Invested Capital for 6 consecutive years, with 0.0% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Invested Capital rose 69.0% year-over-year to 0.0%; the TTM figure through Apr 2026 stood at 0.0% (up 69.0% YoY), while the FY2026 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Invested Capital eased to 0.0% in Q2 2026 per HYFT's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.02% in Q2 2023 and bottomed at 0.8% in Q3 2024.
- Historically, Return on Invested Capital has averaged 0.16% across 5 years, with a median of 0.0% in 2024.
- Annual changes were most pronounced in 2024 — Return on Invested Capital plunged 81 bps — and 2025, when it surged 80 bps.
- MindWalk Holdings' Return on Invested Capital stood at 0.01% in 2022, then surged by 173 bps to 0.01% in 2023, then tumbled by 10573 bps to 0.7% in 2024, then soared by 100 bps to 0.0% in 2025, then slumped by 109 bps to 0.0% in 2026.
- Business Quant data shows HYFT's Return on Invested Capital at 0.0% in Q2 2026, 0.0% in Q1 2026, and 0.0% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 0.00% |
| Jan 31, 2026 | 0.00% |
| Oct 31, 2025 | 0.00% |
| Jul 31, 2025 | 0.00% |
| Apr 30, 2025 | -0.69% |
| Jan 31, 2025 | -0.68% |
| Oct 31, 2024 | -0.70% |
| Jul 31, 2024 | -0.80% |
| Apr 30, 2024 | -0.01% |
| Jan 31, 2024 | 0.00% |
| Oct 31, 2023 | 0.01% |
| Jul 31, 2023 | 0.01% |
| Apr 30, 2023 | 0.02% |
| Jan 31, 2023 | -0.02% |
| Oct 31, 2022 | -0.01% |
| Jul 31, 2022 | -0.01% |
| Apr 30, 2022 | -0.01% |
| Jan 31, 2022 | 0.01% |
| Oct 31, 2021 | 0.01% |
| Jul 31, 2021 | 0.00% |